Nat Commun: Long-term use of Dasatinib and Quercetin can improve intervertebral disc degeneration 

With the extension of human life span, the incidence and impact of age-dependent diseases are also increasing
.

In the recent global survey of 50 chronic diseases, low back pain (LBP) and neck pain ranked first and fourth respectively in terms of years of being unable to take care of themselves

The intervertebral disc is flexible and plays a key role in adapting to the mechanical load of the spine
.

These functional properties are achieved by the interaction of three unique intervertebral disc compartments: the central nucleus pulposus (NP) -avascular tissue, rich in lectins; the circumferential ligament-like fibrous ring (AF)-mainly composed of collagen fibers Composition; and the cartilage inner plate (CEP) bordering the craniofacial and caudal surfaces of NP and AF

Blood vessel

The characteristics of intervertebral disc degeneration include decreased abundance and quality of extracellular matrix (ECM), loss of biomechanical properties, increased inflammatory mediators and catabolic processes, and changes in cell phenotype and death
.

Although the prevalence and disease burden are widespread, there is currently no disease treatment for intervertebral disc degeneration and related disorders

The characteristics of intervertebral disc degeneration include a decrease in the abundance and quality of extracellular matrix (ECM), loss of biomechanical properties, an increase in inflammatory mediators and catabolic processes, and changes in cell phenotype and death.

Studies on human tissues and mouse models have shown that the incidence of senescent cells increases during the aging and degeneration of intervertebral discs
.

The broad characteristics of senescent cells are cell cycle arrest, resistance to apoptosis, and production of catabolic factors called senescence-associated secreted phenotype (SASP)

The broad characteristics of senescent cells are cell cycle arrest, anti-apoptosis, and production of catabolic factors called senescence-associated secreted phenotype (SASP).

The aging drugs Dasatinib and Quercetin can reduce age-dependent disc degeneration and reduce the abundance of aging markers

The aging drugs Dasatinib and Quercetin can reduce age-dependent disc degeneration and reduce the abundance of aging markers.
The aging drugs Dasatinib and Quercetin can reduce age-dependent disc degeneration and reduce the abundance of aging markers.

Recently, due to the link between intervertebral disc degeneration and aging, researchers have explored the ability of the anti-aging drug Dasatinib and Quercetin (D + Q) to prevent the age-dependent progression of the body's intervertebral disc degeneration
.

The researchers started treatment with C57BL/6 mice at 6, 14 and 18 months of age and analyzed them at 23 months of age
.

Interestingly, the 6-month and 14-month D + Q cohorts showed a lower incidence of degeneration , and treatment resulted in a significant reduction in the aging markers p16INK4a and p19ARF, as well as the SASP molecules IL-6 and MMP13

The 6-month and 14-month D+Q cohort showed a lower incidence of degeneration.

Aging drugs may provide an attractive strategy to reduce age-dependent disc degeneration

Original source:

Original source:

Emanuel J.

Emanuel J.

 

Leave a message here